公开(公告)号：EP3854396A1

公开(公告)日：2021-07-28

申请号：EP19861634.4

申请日：2019-09-18

申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

发明人： WANG, Shanchun ,  YU, Ding ,  WANG, Xunqiang ,  PENG, Bangan ,  LIU, Lu ,  DAI, Jie ,  ZHOU, Hang ,  MIAO, Yadong

IPC分类号： A61K31/4709 ,  A61P35/00

摘要： The present application relates to the field of medicine, and provided thereby is a quinoline derivative used for treating small cell lung cancer. The 1-[[[4-(4-fluoro-2-methyl-1 H -indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy] methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof as provided by the present application may be used for the treatment of small cell lung cancer, especially for patients suffering from refractory relapsed small cell lung cancer, which may significantly prolong the survival time thereof; in addition, the therapeutic effect on brain metastatic small cell lung cancer is also very significant.

公开(公告)号：EP4442710A1

公开(公告)日：2024-10-09

申请号：EP22900602.8

申请日：2022-12-01

申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd

发明人： SHEN, Lili ,  ZHANG, Xiquan ,  WANG, Xunqiang ,  YU, Ding ,  LIU, Lu

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/395

CPC分类号： A61K39/395 ,  C07K16/28 ,  A61P35/00

摘要： Provided is a drug combination for treating non-small cell lung cancer, the combination comprising an anti-PD-L1 antibody and a chemotherapeutic drug, and optionally anlotinib or a pharmaceutically acceptable salt thereof. Further provided is the use of the drug combination in the preparation of a drug for treating non-small cell lung cancer.

公开(公告)号：EP4382123A1

公开(公告)日：2024-06-12

申请号：EP22852342.9

申请日：2022-08-05

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

发明人： ZHANG, Xiquan ,  WANG, Xunqiang ,  YU, Ding

IPC分类号： A61K39/395 ,  A61K31/4709 ,  A61P35/00

CPC分类号： A61K39/395 ,  A61P35/00 ,  A61K31/4709

摘要： Provided is a pharmaceutical composition for treating small cell lung cancer, which comprises an anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof, and a chemotherapeutic drug. Further provided is the use of the pharmaceutical composition or a kit containing the anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof and the chemotherapeutic drug in the preparation of a drug for treating small cell lung cancer. Further provided is a method for treating small cell lung cancer, comprising administering to a patient in need thereof a therapeutically effective amount of the anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof, and the chemotherapeutic drug.

公开(公告)号：EP4174087A1

公开(公告)日：2023-05-03

申请号：EP21833511.5

申请日：2021-06-30

申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

发明人： SU, Nan ,  ZHANG, Xiquan ,  CHEN, Jie ,  WANG, Xunqiang ,  LI, Kun ,  YU, Ding ,  WANG, Rongliang

IPC分类号： C07K16/28 ,  C12N15/13 ,  A61K39/395 ,  A61P37/02

摘要： The present invention belongs to the field of biomedicines, relates to a drug for treating tumors, and provides use of an anti-PD-L1 antibody or a pharmaceutical composition thereof in preparation of a drug for treating endometrial cancer. Also provided is use of the anti-PD-L1 antibody or the pharmaceutical composition thereof in preparation of a drug for treating a MSI-H and/or dMMR tumor. In addition, also provided is use of a pharmaceutical combination of the anti-PD-L1 antibody and Anlotinib or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in preparation of a drug for treating endometrial cancer.